Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

7.330 +0.130 (+1.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
3 Stocks To Double Down On In 2022
The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination... 
Via Benzinga
Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients
Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
Analyst Ratings For Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within th... 
Via Benzinga
Expert Ratings For Arvinas
Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following ... 
Via Benzinga
Analyst Ratings For Arvinas
Over the past 3 months, 5 analysts have published their opinion on Arvinas (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients
Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or... 
Via Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
4 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Keybanc raised the price target on Twitter, Inc. (NYSE: TWTR) from $77 to $81. Twitter shares rose 6.4% to $74.00 in pre-market trading. Baird boosted the price target for... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Why Arvinas Jumped 10% Today
The smaller biopharma outfit just inked an encouraging deal with an industry powerhouse. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares climbed 129.7% to $12.75 after the company announced new results from its TATX-03 PolyTope Therapy, demonstrating... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
Arvinas, Pfizer Announce $2.4B Licensing Agreement For Protein-Degrader Based Breast Cancer Therapy
Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) have collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE: 
Via Benzinga
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Arvinas Stock Pops On Buy Rating As Biotech Takes On 'Undruggable Targets'
Arvinas' bid to wrangle "undruggable targets" could reap $4 billion in sales, an analyst said as she initiated coverage of ARVN stock with a buy rating. 
Via Investor's Business Daily
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
75 Biggest Movers From Friday
Gainers The New Home Company Inc. (NYSE: NWHM) jumped 82.9% to settle at $8.89 on Friday after the company agreed to be acquired by funds managed by affiliates of Apollo Global... 
Via Benzinga
50 Stocks Moving In Friday's Mid-Day Session
Gainers Xenetic Biosciences Inc (NASDAQ: XBIO) shares jumped 111.3% to $3.9299 on abnormally-high volume. The New Home Company Inc. (NYSE: NWHM) climbed 83% to $8.90 after the... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares jumped 138.2% to close at $13.22 on Thursday after the company announced new results from its TATX-03 PolyTope Therapy... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021
Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback